Assertio Holdings Inc, the successor issuer to Assertio Therapeutics Inc (NASDAQ: ASRT), has completed the merger with Zyla Life Sciences, it was reported on Wednesday.
The integrated company is to operate under the Assertio name and trade on Nasdaq under the ticker ASRT. The companies say that the merger creates a growing commercial pharmaceutical company with neurology, inflammation and pain products.
The merged company has a board composed of nine directors. Six directors from the pre-merger Assertio board, including Arthur Higgins, the non-executive chairman, Heather L Mason, William T McKee, Peter D Staple, James L Tyree and David E Wheadon and Todd N Smith, Timothy P Walbert, the lead independent director, and Andrea Heslin Smiley joined from the Zyla board.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
AffaMed Therapeutics' DEXTENZA NDA accepted by Singapore regulator
AbbVie showcases gastroenterology portfolio at ECCO Congress
Japan approves Sanofi's Dupixent for chronic spontaneous urticaria
Ono partners with Shattuck Labs for bifunctional fusion proteins
Zymedi commences first in human dosage of ZMA001
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
EicOsis Human Health commences EC5026 Phase 1b multiple-ascending dose clinical trial
Takeda's HyQvia approved for maintenance therapy in CIDP patients
Celltrion USA submits CT-P47 Biologics License Application to FDA
Formosa Pharmaceuticals agrees licensing deal in Brazil for APP13007